Virtu Financial LLC Invests $207,000 in Roivant Sciences Ltd. (NASDAQ:ROIV)

Virtu Financial LLC acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 17,917 shares of the company’s stock, valued at approximately $207,000.

Several other hedge funds have also recently added to or reduced their stakes in ROIV. Clearbridge Investments LLC grew its position in shares of Roivant Sciences by 51.3% in the second quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company’s stock valued at $19,666,000 after purchasing an additional 630,712 shares during the last quarter. Point72 Asset Management L.P. increased its position in Roivant Sciences by 40.1% during the second quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company’s stock worth $6,840,000 after buying an additional 185,226 shares in the last quarter. Exchange Traded Concepts LLC acquired a new position in shares of Roivant Sciences in the third quarter worth $2,267,000. TOMS Capital Investment Management LP purchased a new stake in shares of Roivant Sciences in the third quarter valued at $46,333,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Roivant Sciences during the second quarter valued at $472,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ROIV has been the topic of a number of recent research reports. Bank of America upped their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a report on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.93.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $11.69 on Thursday. Roivant Sciences Ltd. has a 1-year low of $9.69 and a 1-year high of $13.06. The firm has a market capitalization of $8.51 billion, a P/E ratio of 2.07 and a beta of 1.25. The business’s 50-day simple moving average is $11.92 and its 200-day simple moving average is $11.47.

Insider Activity at Roivant Sciences

In related news, Director Keith S. Manchester sold 368,052 shares of the stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $11.62, for a total value of $4,276,764.24. Following the completion of the sale, the director now directly owns 1,412,126 shares in the company, valued at approximately $16,408,904.12. This represents a 20.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00. Following the transaction, the chief operating officer now owns 606,525 shares in the company, valued at approximately $6,865,863. This represents a 14.15 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,677,309 shares of company stock worth $43,283,184. Company insiders own 7.90% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.